Amryt Pharma (#AMYT) – $40m placing at equivalent of $2.50 per share
- 2020-12-08 07:59:13
UK 15:28 Monday, 26 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Hello Share Chewers. Small pioneering medical companies are a favourite of mine. As finding a cure for a condition which is so often overlooked by the giant pharmas has to be a good thing. Both from the point of view of patients and that of shareholders.
We still have some warrants in Amryt (AMYT) and I know this is a big year both in terms of clinical trials and also sales ramp up but I admit that I am a bit off the pace on exactly what is going on. So over to someone who is bang up to speed.
Hello Share Trundlers. Today’s commendation is one of those companies that you can take pride in supporting because it’s such a jolly humanity-serving idea. And in this case, the prognosis, in my humble opinion, looks rather good.
With its shares having reached 25.75p last week and closed at above 25p on Wednesday, Amryt Pharma (AMYT) announced on Thursday that it was “delighted with the support we have received” for an “oversubscribed placing”, raising a gross €15 million (£13.3 million)… at 20p per share! As a long standing shareholder I say "F**k you." I feel so utterly 100% shafted as will those who paid 26p+ last week after confident results which made it clear that Amryt was fully funded. So I asked Steve Moore to pen an analysis. As I explained in Thursday's bearcast HERE I am too angry to be objective. The fact is that at a 22.5p offer the shares are a BUY.
This is sad news for sufferers of for Epidermolysis Bullosa (EB) but very good news for we shareholders in Amryt Pharma (AMYT). Overnight last Thursday, the rival, Amicus announced that its Phase 3 asset SD-101 for Epidermolysis Bullosa has failed in Phase 3. The drug failed to meet all co-primary and secondary endpoints, which could suggest that there was minimal/no biological effect.
Amryt Pharma (AMYT) has announced results for the six months ended 30 June 2017. There were no great shocks the buy case is compelling and low risk - my target, for shares I admit to owning, is very conservative. Others are twice as ambitious or more!
Amryt Pharma (AMYT) has announced new data from a long-term safety and efficacy study of Lojuxta in the treatment of Homozygous Familial Hypercholesterolaemia (HoFH). Try saying that after half a bottle orf whiskey. Remember that Lojuxta which was licensed in last December is the second of three strings to the Amryt bow.
Amryt Pharma (AMYT) held its AGM yesterday and the statement seems to hint that forecasts are going to have to be raised. It is a very bullish statement indeed. The company states:
Take a look! European investors are clearly failing to grasp the very significant financial and commercial benefits available for Orphan or Rare Disease drug developers. So much so in fact, that sector-focussed Amryt Pharma (AMYT) finds no quoted peers in London, yet a good basket of NASDAQ-listed comparables are seen to command a significant premium despite mostly being pre-revenue and somewhat earlier in their development. Such anomalies can and, of course, do rapidly correct.
Many people think that the excitement about Amryt (AMYT) is down to its EB treatment where phase three trials are now underway. Well that is a lot of excitement but there is far more as the latest news makes clear.
Amryt Pharma (AMYT) has announced that the first patient has now been enrolled in its phase three trial of AP101, a potential treatment for the rare, genetic skin disorder, Epidermolysis Bullosa - a market worth £1 billion.
Shares in Amryt Pharma (AMYT) have surged to 26p-26.5p so we are well up on the share tip price (18.4p offer) and within spitting distance of the 28p+ to sell target. But hang on tight pro tem...
It is a sign of the times that three of the ten pages in this broker note are covering regulatory disclosures. Stifel acts as broker to Amryt (AMYT) so feel free to disregard all that it says. None the less, since FIML owns a shed load of these shares, a prediction that the stock should treble is surely worth reporting.
These historic numbers from Amryt Pharma (AMYT) are pretty academic. In fact they are more or less irrelevant. But…
Shares in Amryt Pharma (AMYT) are starting to move the right way and ever faster as clear progress is made with its portfolio. On Tuesday we had the, not unexpected, news that it has started the phase 3 ( that is to say final human) trials of AP101, its lead drug candidate, a potential treatment for Epidermolysis Bullosa (EB). EB is a rare, genetic skin disorder, which causes exceptionally fragile skin.
